Global Alpha-1 Antitrypsin Deficiency Therapy Market -2023-2030

Overview

The global alpha-1 antitrypsin deficiency therapy market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The chance of developing lung and additional illnesses increases if the person have an AAT deficiency. AAT is a protein produced in the liver that aids in lung defense. The lungs are more vulnerable to injury from smoking, air pollution, and environmental dust if the body fails to produce enough AAT.

Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products or therapies and boost the global alpha-1 antitrypsin deficiency therapy market. The respective innovative products includes the use of novel treatments such as augmentation therapy for better management.

Market Dynamics: Drivers & Restraints

Growing regulatory approvals for augmentation therapy

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for alpha-1 antitrypsin deficiency therapy owing to the positive outcomes in research. Various regulatory approvals for product launch among different countries will be a crucial factor driving the growth of the market.

On May 16, 2023, Glassia [Alpha-1 Proteinase Inhibitor (Human)] got approval for marketing in Switzerland for long-term augmentation along with maintenance treatment in adults having clinically diagnosed emphysema caused by severe hereditary Alpha-1 antitrypsin deficiency (AA), according to a report from Kamada Ltd., a commercial phase global biopharmaceutical business with a portfolio of marketed drugs indicated for rare and severe medical conditions.

Furthermore, the rising utilization of novel therapies or drugs for the management of alpha-1 antitrypsin deficiency. Rising awareness among people and increasing research for innovative product development will be a major factor driving the growth of the alpha-1 antitrypsin deficiency therapys market.

Side effects associated with the augmentation therapy

Although several negative effects of augmentation therapy have been recorded by alphas, the majority never experience any serious issues. The most frequent adverse reaction is fatigue or flu-like symptoms, which can persist for as long as 24 hours following an infusion. Slowing down the pace of infusion can frequently decrease or even get rid of these symptoms.

Itching, rash, hives, dyspnea, tightness in the chest, and wheezing are some of the symptoms that some Alphas have that resemble mild allergic reactions. If patients take an antihistamine like Benadryl prior to their infusions, many of those can continue getting augmentation therapy. Very seldom, adverse effects are bad enough to have an Alpha completely quit their augmentation medication.

Segment Analysis

The global alpha-1 antitrypsin deficiency therapy market is segmented based on therapy, route of administration, end user and region.

Augmentation Therapy segment accounted for approximately 43% of market share

Patients with significant alpha-1 antitrypsin (AAT) insufficiency who have emphysema may benefit from augmentation therapy, sometimes referred to as replacement therapy. The level of alpha-1 antitrypsin (AAT) in the lungs of patients having AAT deficiency is increased using alpha-1 antitrypsin protein obtained from the blood of healthy donors. AAT guards against lung damage caused by the immune system in healthy people. AAT augmentation therapy helps individuals with AAT deficiency increase the quantity of AAT in their lungs, preventing additional lung damage.

On July 13, 2023, a phase 3 clinical trial to ascertain whether alpha-1-antitrypsin (AAT) deficiency (alpha-1) individuals who have emphysema have a more gradual rate of lung tissue lack when handled weekly with two distinct dose regimens of Grifols Prolastin-C has reached its enrollment goal of 339 patients, according to Grifols, one of the world's top producers of plasma-derived medications.

Prolastin-C has the potential to substantially slow the development of emphysema in alpha-1 patients by increasing AAT protein levels via weekly administration of two successful dose levels compared to placebo, according to SPARTA, the largest randomized, placebo-controlled, double-blind, study on AAT augmentation treatment to date.

Geographical Penetration

North America accounted for around 38% of market share in 2022

Due to the rising need for alpha-1 antitrypsin deficiency therapy in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for alpha-1 antitrypsin deficiency therapy.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different kinds of therapies for management, and increase in pharmaceutical or biotechnology business establishment across the region are also contributing to the growth of alpha-1 antitrypsin deficiency therapy market share of this region. The market in this area is growing as people become more aware of various novel innovative therapies such as Prolastin-C. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global alpha-1 antitrypsin deficiency therapy market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for alpha-1 antitrypsin deficiency therapy in the U.S. United States have been proactive in executing several initiatives or researches, stimulating alpha-1 antitrypsin deficiency therapy demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global alpha-1 antitrypsin deficiency therapy market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical device industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for alpha-1 antitrypsin deficiency therapy. Now several research studies have been initiated and companies have again started trial for their products safety and efficacy. Overall, the impact of the pandemic on the global alpha-1 antitrypsin deficiency therapy market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel therapies, like augmenting therapies and other programs for management of alpha-1 antitrypsin deficiency.

Key Developments

• On May 23, 2023, data about the Phase 2 "ASTRAEUS" investigation of alvelestat for the management of Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD), along with post-hoc analyses illustrating the association among biomarker reductions using alvelestat and enhancements in SGRQ, a significant Patient-Reported Results (PRO) measure, have been presented for the very first time to the scientific world by Mereo BioPharma Group plc, a clinical-stage biopharmaceutical business focused on rare diseases.
• On January 9, 2023, topline findings from the Phase 2 SEQUOIA research trial of the investigational drug fazirsiran (TAK-999/ARO-AAT) for the management of liver disease brought on by alpha-1 antitrypsin deficiency (AATD-LD) were disclosed by Takeda and Arrowhead Pharmaceuticals Inc. A Phase 3 study that was created jointly by Takeda and Arrowhead and would be carried out by Takeda was also outlined by the firms.

Competitive Landscape

The major global players in the market include: Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, CSL, Vertex Pharmaceuticals Incorporated, Grifols, Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Inhibrx, Inc., Wave Life Sciences and Mereo Biopharma Group PLC among others.

Why Purchase the Report?

• To visualize the global alpha-1 antitrypsin deficiency therapy market segmentation based on therapy, route of administration, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of alpha-1 antitrypsin deficiency therapy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global alpha-1 antitrypsin deficiency therapy market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies